Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it intends to offer $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 7.18%. On last trading day company shares ended up $7.02. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is 0.15%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 3.69% in last trading session and ended the day on $6.18. ARNA Gross Margin is 93.70% and its return on assets is -8.10%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -13.45%.
On 30 MAY MannKind Corporation (NASDAQ:MNKD) announced that the company will present conferences during June 2014. Global Healthcare Conference in a presentation scheduled to begin at 02:30 p.m. (ET) in New York City. On Thursday, June 12, 2014, the company will represent at Goldman Sachs 35th Annual Global Healthcare Conference in a presentation scheduled to begin at 11:20 a.m. (PT) in California. Lately, the company will present on Tuesday, June 17, 2014, at Wells Fargo 2014 Healthcare Conference during a presentation scheduled to begin at 10:00 a.m. (ET) in Boston. MannKind Corporation (NASDAQ:MNKD) shares moved down -2.66% in last trading session and was closed at $10.25, while trading in range of $10.10 – $10.54. MannKind Corporation (NASDAQ:MNKD) year to date (YTD) performance is 99.04%.
On 10 JUNE Gilead Sciences, Inc. (NASDAQ:GILD) reported that Gilead Sciences, Inc. (NASDAQ:GILD)’s revenues grew by 104% in 1Q2014 compared to 1Q2013 to reach $4.87 billion — beating estimates of $3.96 billion by 26.38% or nearly $1 billion. This spectacular growth was fueled by Gilead’s anti-viral products and above all Sovaldi, its blockbuster Hepatitis C virus (HCV). Gilead Sciences, Inc. (NASDAQ:GILD) ended the last trading day at $80.82. Company weekly volatility is calculated as 2.32% and price to cash ratio as 19.19. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -2.65%.
On 10 JUNE Idenix Pharmaceuticals Inc (NASDAQ:IDIX) said it believes that the agreement between Idenix Pharmaceuticals Inc (NASDAQ:IDIX) and Merck & Co. creates value for its shareholder by aligning its strong portfolio of candidates with a well-known global healthcare company for its future success. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) weekly performance is 246.98%. On last trading day company shares ended up $23.56. Analysts mean target price for the company is $5.80. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) distance from 50-day simple moving average (SMA50) is 259.50%.